DRAP

Drug Regulatory Authority of Pakistan (DRAP) has founded some impurities in a common medicine which is used for controlling high blood pressure the led to heart failures. The decision was made after some scientists performed experiments and examine impurities in raw materials of Valsartan and it is manufactured by M/S Zhejiang Huahai Pharmaceutical Co. Ltd, China.

Valsartan medicine is usually used to treat patients with high blood pressure to reduce the heart complications. According to the survey of Journal Pakistan Medical Association & National Health 2011, Almost 33 percent of Pakistani people above the age of 45 are suffering from hypertension with 19 percent of generality among people of age 15 or above from it.

The impurities which the researchers found in these materials and from which Valsartan is processed could mainly cause cancer. Due to this DRAP has announced that total nine pharmaceutical companies in Pakistan who sell this medicine and a notice will be sent to those companies to terminate the manufacturing of this medicine. Moreover, Getz Pharma and its’ products, Cova, Covam, & Cova-H are not included in the list.

Read also: The first ever Hajj Hackathon registration opened for organizers and techies

Getz Pharma has issued a statement regarding the Valsartan brands which manufactured using the raw material or Active Pharmaceutical Ingredients (APIs) sourced the material according to the world health organization (WHO) guidelines. The Company also said that its staff is pre-qualified and approved by WHO Geneva, too, from a member country which is Pharmaceutical Inspection Co-operation Scheme (PIC/S). It also operates in 22 countries across the world.

People who have been consuming Valsartan pills from quite a while are advised to visit their Healthcare consultant as soon as possible and to take necessary measures to prevent yourself from any harm. So any of you still using it you are directed to stop using it.

You may also like

More in Social

0 0 vote
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments